Turn Therapeutics Inc. has scheduled its annual meeting of stockholders for November 30, 2026. This meeting will be held virtually and is significant for shareholders as it will cover important proposals, including the election of two Class I directors and the ratification of the appointment of WithumSmith+Brown, PC as the company’s independent registered public accounting firm.

The meeting is set to take place at 12:00 p.m. Eastern Time and will be accessible online. Shareholders will have the opportunity to vote electronically and submit questions to management during the meeting. This event is a critical platform for shareholders to engage with the company’s leadership and influence its strategic direction.

Turn Therapeutics, incorporated in Delaware, operates within the pharmaceutical preparations industry, as classified under SIC 2834. The company trades on the Nasdaq under the ticker symbol TTRX. As an emerging growth company, Turn Therapeutics is focused on developing innovative therapies to meet unmet medical needs.

The proxy statement filed on October 19, 2026, outlines the agenda for the upcoming meeting. It states, “The Proxy Statement for the Annual Meeting contains important information about the Annual Meeting and each of the proposals.” This document will be distributed to stockholders on or around the filing date.

The annual meeting is expected to impact shareholders, as it will determine the composition of the board of directors and the auditors overseeing the financial statements for the fiscal year ending December 31, 2026. The company has set October 5, 2026, as the record date for determining the stockholders entitled to vote at the meeting.

Looking ahead, shareholders are encouraged to participate in the voting process, whether or not they attend the virtual meeting. The filing emphasizes the importance of shareholder participation, stating, “Your vote is important.” Instructions for voting will be included in the proxy statement and accompanying materials.

For more information and to access the proxy materials, shareholders can visit www.proxydocs.com/TTRX.